about
Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized miceAntiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT miceImmune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection.Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence researchSystemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT miceRectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized miceTargeted cytotoxic therapy kills persisting HIV infected cells during ARTIn vivo analysis of highly conserved Nef activities in HIV-1 replication and pathogenesis.Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection.One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidatesHypogammaglobulinemia in BLT humanized mice--an animal model of primary antibody deficiency.Generation of HIV latency in humanized BLT mice.The Depsipeptide Romidepsin Reverses HIV-1 Latency In VivoNef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes.Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions.Mucosal HIV-1 transmission and prevention strategies in BLT humanized miceCryptopatches are essential for the development of human GALT.Novel humanized murine models for HIV research.Broad activation of latent HIV-1 in vivo.Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy.Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon.Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.Immune checkpoints and the HIV-1 reservoir: proceed with caution.Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients.Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections.Predictive value of galectin-1 in the development and progression of HIV-associated lymphoma.CD8+ T cells reduce in vitro interferon-gamma production in Theiler's murine encephalomyelitis virus-induced demyelinating disease model.Susceptibility to Theiler's murine encephalomyelitis virus-induced demyelinating disease in BALB/cAnNCr mice is related to absence of a CD4+ T-cell subset.The role of miR-29a in HIV-1 replication and latency.Acute Appendicitis as the Initial Clinical Presentation of Primary HIV-1 Infection.Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses.Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1.Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individualsInterferon priming is essential for human CD34+ cell-derived plasmacytoid dendritic cell maturation and functioncAIMP administration in humanized mice induces a chimerization‐level‐dependent STING responseCharacterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption
P50
Q21131400-6A267B17-FA35-4417-A738-EE6B7B16A57CQ21144657-919276BB-9888-41B8-9686-44CF657902F6Q27692578-1D5BCBB9-73F1-48D7-96CB-3A1000A794D8Q28077662-894665FA-FF7F-45E9-9C46-31076A57F5A4Q28472590-1B1E9683-FBE9-4C03-A1CF-704967CD9BE5Q28488527-CB58B107-571B-4EE7-9E8A-768A6B592CEFQ28538598-E5557AF3-6608-4CED-B334-AF486A369152Q30009533-2F7EEA19-E401-4E2B-A71C-3896FF0A0DD5Q33754991-4C0A20F6-4C8F-4CC1-A55A-C5622B4A140FQ35140303-95585767-5D13-4EE3-A8AD-D81761012CA0Q35291397-C73F340F-86C6-4254-A43E-E7610A78E02AQ35666126-66B8217F-F2A3-4FAC-B44D-4A150E010814Q35778783-A5719D32-8D0B-4BBF-B6E2-AE31BEDF9430Q36112824-D3066332-9DE4-4B87-8C03-0CD47B7271F2Q36229284-E796950C-8661-49EF-96DD-05343AF9F848Q36618563-71009169-521F-4CC4-A66F-A20092891010Q36923075-9453360E-18F7-436F-9810-7A060BCA50CEQ37049642-69488F22-BAE2-43C7-B607-66C04F4711E5Q37084504-2392B985-4BA3-4743-852A-78A60A8BAE0AQ37260309-0E28C766-D8BB-4FD3-9920-1E8966588632Q37618260-C18431B6-7806-4525-BA36-8491D399275BQ38939957-36E1FC9D-7D12-499F-9589-300EFF1A371EQ39361321-6C93CB1B-8AF2-42EA-B674-2A48DD0D6B9CQ40098403-4E37DE5F-A798-41AE-B1A0-631C1A5A8FDFQ40280217-67286E94-8183-4BA2-ADF6-B04A4E9398B7Q40336664-38207127-2450-4A2B-8705-9CF0D17DE9D6Q40591659-22BDE6D3-0353-43FA-8FAE-4D246D2FF045Q40860152-23A39F2E-5BDF-46DE-BB6D-1CC1E6021FE2Q41036069-3635076A-2596-4398-97F4-E02BEE310D82Q41989712-A5AF3D07-D6CB-4BF5-8640-D72A8004FC24Q45597208-A418396D-E669-4104-9F4A-8F2176DE4600Q45729904-D3A02467-4488-46D4-A3C5-5F11F38B7436Q47604571-71F91F7F-8153-4614-892D-D818FB1B2C83Q49268446-4BD4C3E4-AB47-4857-AE7A-DC3BCDE474BCQ50281172-8CCE7520-BC89-466D-9C76-317C9D1E1443Q53592113-96F361BB-1E8A-4766-BC54-DE1C4D1B4217Q57201701-05B9055A-1EB8-4DD9-90E5-E0D663ADA0DCQ60222268-92E0DBC3-4A83-44DE-9D50-0AABD6291D76Q63727538-53C29BDB-9AC0-40F6-A5F2-8FBC6A1D99B1Q63728944-82AE1852-7F1D-4C91-89CD-7F49DD05D06C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Paul W Denton
@nl
Paul W Denton
@sl
Paul W. Denton
@en
Paul W. Denton
@es
type
label
Paul W Denton
@nl
Paul W Denton
@sl
Paul W. Denton
@en
Paul W. Denton
@es
prefLabel
Paul W Denton
@nl
Paul W Denton
@sl
Paul W. Denton
@en
Paul W. Denton
@es
P108
P214
P244
P106
P108
P1153
35760080200
P21
P213
0000 0000 4220 7852
P214
P244
no2002080433
P31
P496
0000-0003-2458-8147
P735
P7859
lccn-no2002080433